Stromal expression of cancer-associated fibroblast-related molecules, versican and lumican, is strongly associated with worse relapse-free and overall survival times in patients with esophageal squamous cell carcinoma.

cancer-associated fibroblasts esophagus lumican periostin squamous cell carcinoma versican

Journal

Oncology letters
ISSN: 1792-1074
Titre abrégé: Oncol Lett
Pays: Greece
ID NLM: 101531236

Informations de publication

Date de publication:
Jun 2021
Historique:
received: 19 09 2020
accepted: 26 02 2021
entrez: 19 4 2021
pubmed: 20 4 2021
medline: 20 4 2021
Statut: ppublish

Résumé

Cancer-associated fibroblasts (CAFs) in the tumor microenvironment play an essential role in the tumor progression of esophageal squamous cell carcinoma (ESCC). The present study aimed to investigate the expression of CAF-related molecules, versican, periostin and lumican, in cancer stroma, to provide prognostic stratification for patients with ESCC after surgery. A total of 106 patients with ESCC who underwent curative esophagectomy without preoperative chemotherapy or radiotherapy were enrolled. The expression of CAF-related stromal proteins, including versican, periostin and lumican, was examined using immunohistochemistry, and the prognostic value was assessed by Kaplan-Meier survival analysis, and univariate and multivariate Cox regression models. The expression of versican, periostin and lumican was found specifically in the stromal component of ESCC. Kaplan-Meier analysis demonstrated that, compared with a low expression level, a high expression level of versican, periostin or lumican in the cancer stroma was significantly associated with worse relapse-free survival (RFS) and overall survival times in patients with ESCC. The prognostic values of stromal versican and lumican remained significant in a stratified analysis of stage I patients. Moreover, univariate and multivariate analysis revealed that high stromal versican or lumican expression was an independent prognostic factor for RFS in the patients. The present study demonstrated that CAF-related molecules, including versican, periostin and lumican, were expressed in the stroma of ESCC, and that stromal expression of versican and lumican in particular may have clinical utility as a prognostic biomarker for poor RFS in postoperative patients with ESCC.

Identifiants

pubmed: 33868483
doi: 10.3892/ol.2021.12706
pii: OL-0-0-12706
pmc: PMC8045151
doi:

Types de publication

Journal Article

Langues

eng

Pagination

445

Informations de copyright

Copyright: © Yamauchi et al.

Déclaration de conflit d'intérêts

The authors declare that they have no competing interests.

Références

Histol Histopathol. 2013 Jun;28(6):701-13
pubmed: 23519970
World J Surg. 2009 Jul;33(7):1439-45
pubmed: 19440651
Int J Mol Sci. 2015 May 27;16(6):12108-18
pubmed: 26023718
Oncogenesis. 2015 Nov 30;4:e178
pubmed: 26619403
Med Sci Monit. 2017 Jun 30;23:3200-3208
pubmed: 28665915
Oncol Lett. 2017 Jul;14(1):376-382
pubmed: 28693179
Cancer Res. 2013 Aug 15;73(16):5016-28
pubmed: 23824740
Sci Rep. 2017 Dec 8;7(1):17225
pubmed: 29222454
Clin Cancer Res. 2003 Jan;9(1):207-14
pubmed: 12538471
Cancer Res. 2010 Jul 1;70(13):5281-92
pubmed: 20516120
Carcinogenesis. 2016 Sep;37(9):878-887
pubmed: 27287872
Anal Cell Pathol (Amst). 2020 Jan 8;2020:6283796
pubmed: 32377504
Gynecol Oncol. 2010 Nov;119(2):337-44
pubmed: 20688362
Cells. 2020 Feb 17;9(2):
pubmed: 32079295
Mol Ther. 2013 May;21(5):1004-13
pubmed: 23511245
World J Gastroenterol. 2013 Sep 14;19(34):5598-606
pubmed: 24039351
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Int J Clin Exp Pathol. 2014 Jan 15;7(2):593-601
pubmed: 24551279
Clin Cancer Res. 2016 Oct 1;22(19):4934-4946
pubmed: 27126993
Cancer Biol Ther. 2009 Jan;8(1):36-46
pubmed: 18981721
Matrix Biol. 2014 Jul;37:150-6
pubmed: 24813586
Cancer Res. 1998 Apr 1;58(7):1348-52
pubmed: 9537227
Asian Pac J Trop Med. 2013 Jul;6(7):516-9
pubmed: 23768821
Acta Med Iran. 2013;51(11):740-50
pubmed: 24390942
Int J Cancer. 2003 Mar 20;104(2):161-6
pubmed: 12569570
Oncol Rep. 2007 Sep;18(3):537-43
pubmed: 17671699
Nat Genet. 2015 Apr;47(4):320-9
pubmed: 25706628
Clin Cancer Res. 1998 Apr;4(4):963-71
pubmed: 9563891
Sci Rep. 2016 Feb 09;6:20587
pubmed: 26857387
Int J Mol Sci. 2011 Jan 31;12(2):1009-29
pubmed: 21541039
Tumour Biol. 2015 May;36(5):3171-7
pubmed: 25840689
Int J Oncol. 2011 Jun;38(6):1759-66
pubmed: 21468544
PLoS One. 2014 Dec 02;9(12):e112300
pubmed: 25464508
Mol Med Rep. 2013 Mar;7(3):875-80
pubmed: 23314871
Methods Mol Biol. 2020;2129:1-6
pubmed: 32056165
Transl Oncol. 2019 Mar;12(3):475-484
pubmed: 30594036
Ann Oncol. 2007 Feb;18(2):269-74
pubmed: 17065588
J Pathol. 2015 Feb;235(3):466-77
pubmed: 25345775
Chin J Cancer. 2012 Jun;31(6):281-6
pubmed: 22507220
Clin Cancer Res. 2004 Apr 1;10(7):2491-8
pubmed: 15073129

Auteurs

Naoto Yamauchi (N)

Department of Gastrointestinal Tract Surgery, Fukushima Medical University, Fukushima 960-1295, Japan.

Yasuyuki Kanke (Y)

Department of Gastrointestinal Tract Surgery, Fukushima Medical University, Fukushima 960-1295, Japan.

Katsuharu Saito (K)

Department of Gastrointestinal Tract Surgery, Fukushima Medical University, Fukushima 960-1295, Japan.

Hirokazu Okayama (H)

Department of Gastrointestinal Tract Surgery, Fukushima Medical University, Fukushima 960-1295, Japan.

Shoki Yamada (S)

Department of Diagnostic Pathology, Fukushima Medical University, Fukushima 960-1295, Japan.

Shotaro Nakajima (S)

Department of Gastrointestinal Tract Surgery, Fukushima Medical University, Fukushima 960-1295, Japan.

Eisei Endo (E)

Department of Gastrointestinal Tract Surgery, Fukushima Medical University, Fukushima 960-1295, Japan.

Koji Kase (K)

Department of Gastrointestinal Tract Surgery, Fukushima Medical University, Fukushima 960-1295, Japan.

Leo Yamada (L)

Department of Gastrointestinal Tract Surgery, Fukushima Medical University, Fukushima 960-1295, Japan.

Hiroshi Nakano (H)

Department of Gastrointestinal Tract Surgery, Fukushima Medical University, Fukushima 960-1295, Japan.

Takuro Matsumoto (T)

Department of Gastrointestinal Tract Surgery, Fukushima Medical University, Fukushima 960-1295, Japan.

Hiroyuki Hanayama (H)

Department of Gastrointestinal Tract Surgery, Fukushima Medical University, Fukushima 960-1295, Japan.

Yohei Watanabe (Y)

Department of Gastrointestinal Tract Surgery, Fukushima Medical University, Fukushima 960-1295, Japan.

Suguru Hayase (S)

Department of Gastrointestinal Tract Surgery, Fukushima Medical University, Fukushima 960-1295, Japan.

Motonobu Saito (M)

Department of Gastrointestinal Tract Surgery, Fukushima Medical University, Fukushima 960-1295, Japan.

Zenichiro Saze (Z)

Department of Gastrointestinal Tract Surgery, Fukushima Medical University, Fukushima 960-1295, Japan.

Kosaku Mimura (K)

Department of Gastrointestinal Tract Surgery, Fukushima Medical University, Fukushima 960-1295, Japan.

Tomoyuki Momma (T)

Department of Gastrointestinal Tract Surgery, Fukushima Medical University, Fukushima 960-1295, Japan.

Shinji Oki (S)

Department of Gastrointestinal Tract Surgery, Fukushima Medical University, Fukushima 960-1295, Japan.

Yuko Hashimoto (Y)

Department of Diagnostic Pathology, Fukushima Medical University, Fukushima 960-1295, Japan.

Koji Kono (K)

Department of Gastrointestinal Tract Surgery, Fukushima Medical University, Fukushima 960-1295, Japan.

Classifications MeSH